CARECLOUD(CCLDO) - 2024 Q3 - Quarterly Report

Financial Performance - For the three months ended September 30, 2024, net revenue was $28,546,000, a decrease of 2.5% from $29,280,000 in the same period of 2023[151]. - Adjusted EBITDA for the nine months ended September 30, 2024, was $16,916,000, an increase of 49.5% compared to $11,301,000 for the same period in 2023[151]. - GAAP net income for the three months ended September 30, 2024, was $3,122,000, compared to a loss of $2,749,000 in the same period of 2023[151]. - Adjusted net income for Q3 2024 was $3.471 million, compared to $203,000 in Q3 2023, reflecting a significant increase[153]. - GAAP net income for Q3 2024 was $3.122 million, a turnaround from a loss of $2.749 million in Q3 2023[153]. - Total revenue for Q3 2024 was $28.546 million, a decrease of 3% from $29.280 million in Q3 2023[170]. - The income before income taxes for the three months ended September 30, 2024, was $3.2 million, compared to a loss of $2.7 million for the same period in 2023[197]. Cost Management - Direct operating costs as a percentage of revenue decreased to 54.0% in Q3 2024 from 62.4% in Q3 2023[170]. - Selling and marketing expenses decreased to 4.8% of revenue in Q3 2024 from 8.0% in Q3 2023[170]. - Direct operating costs decreased by $2.8 million (16%) for the three months and $8.0 million (15%) for the nine months ended September 30, 2024, compared to the same periods in 2023[172]. - Selling and marketing expenses decreased by $962,000 (41%) for the three months and $2.7 million (36%) for the nine months ended September 30, 2024, compared to the same periods in 2023[173]. - General and administrative expenses decreased by $1.1 million (20%) for the three months and $4.4 million (27%) for the nine months ended September 30, 2024, compared to the same periods in 2023[174]. - Research and development expenses decreased by $460,000 (37%) for the three months and $755,000 (21%) for the nine months ended September 30, 2024, compared to the same periods in 2023[175]. Operational Efficiency - Non-GAAP adjusted operating margin for the three months ended September 30, 2024, was 12.9%, compared to 1.8% in the same period of 2023[151]. - The company’s GAAP operating margin for the three months ended September 30, 2024, was 11.4%, compared to a negative margin of 6.7% in the same period of 2023[151]. - The company employs approximately 330 health industry experts in the U.S. and 3,300 offshore team members, achieving significant cost reductions[146]. - The company’s technology solutions include AI-powered clinical decision support and virtual support assistant, enhancing operational efficiency and patient care[145]. Cash Flow and Capital Management - The company had total cash of $2.8 million and net working capital of $732,000 as of September 30, 2024[186]. - Cash provided by operations was $15.4 million, offset by cash used in investing and financing activities of $15.8 million, resulting in a decrease in cash of $549,000 for the nine months ended September 30, 2024[186]. - For the nine months ended September 30, 2024, net cash provided by operating activities was $15.4 million, an increase of 31% compared to $11.7 million for the same period in 2023[198]. - Net cash used in investing activities decreased to $5.1 million for the nine months ended September 30, 2024, down 45% from $9.3 million in 2023[199]. - Net cash used in financing activities was $10.7 million for the nine months ended September 30, 2024, compared to $8.4 million in 2023, reflecting an increase of 27%[200]. - Capital expenditures for the nine months ended September 30, 2024, were $759,000, significantly lower than $2.7 million in 2023[199]. - Software development costs capitalized for the nine months ended September 30, 2024, were $4.4 million, down from $6.6 million in 2023[199]. Market and Operational Insights - Revenue from technology-enabled business solutions accounted for approximately 63% of total revenue in Q3 2024, slightly down from 64% in Q3 2023[157]. - Medical practice management services generated approximately 15% of revenue in Q3 2024, up from 13% in Q3 2023[158]. - The company served approximately 40,000 providers as of September 30, 2024, consistent with the previous year[156]. - The company continues to monitor inflation impacts and believes it can pass on price increases for fixed-rate contracts to customers[195]. Cybersecurity and Risk Management - The company has not identified any compromise or unauthorized access of its systems due to the Change Healthcare cybersecurity incident as of September 30, 2024[192]. - The Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on its financial results[193]. - The company has not experienced any losses on cash accounts held at banks in Pakistan and Sri Lanka, despite the lack of deposit insurance coverage in these countries[139]. Future Outlook - Management expects approximately $22.0 million in annualized cost savings, with about $16.0 million realized during 2024[188]. - The company suspended its Preferred Stock dividend in December 2023, leading to a goodwill impairment charge, but as of September 30, 2024, stock prices increased, resulting in no impact on goodwill valuation[140].